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We describe a 64-year-old man with extensive diffuse acute lung hemorrhage, presumably as a result of
anticoagulation therapy. We evaluated reports in the literature concerning acute exacerbation (acute
lung injury of unknown cause) in UIP and other forms of ﬁbrotic interstitial pneumonias. We also
evaluated autopsy tissue in this case in order to determine the cause of death in this 64-year-old man,
who was initially thought to have an asbestos-related disease. Based on the autopsy ﬁndings, this man
died as a result of anticoagulation therapy; speciﬁcally, the use of Xarelto® (rivaroxaban).
© 2015 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case report
A 64-year-old Caucasian male underwent right total knee
replacement on December 4, 2013 and was subsequently pre-
scribed a 21-day supply of the anticoagulation drug Xarelto®
(rivaroxaban), 10 mg by mouth every day with dinner. Approxi-
mately two weeks had elapsed since he stopped taking Xarelto
when, on January 13, 2014, the patient was admitted to the hospital
with a violent, nonproductive cough and extreme shortness of
breath. He denied fever. He had an elevated white blood cell count
of 20,400 K/uL. CT scan showed ground-glass opacity and bilateral
atypical pneumonia. He was treated with antibiotics (azithromycin
500 mg daily and ceftriaxone 100 mL NS, 1 g q24h). He was started
on subcutaneous heparin (enoxaparin 40 mg/0.4 mL) at bedtime
between 1/14/14 and 1/26/14 for prevention of deep venous
thrombosis (DVT)/pulmonary embolism (PE) for a total of 12 doses.
Other medical problems included pulmonary nodules; prostatic
hyperplasia; obstructive sleep apnea; hyperlipidemia; left shoulder
rotator cuff repair; and recent knee replacement surgery. He had a
prior history of asbestos exposure and there was concern he might
have an asbestos-related disease.
A chest radiograph and CT scan showed stable cardiomegaly, a
right pneumothorax, diffuse interstitial thickening with patchy
airspace opacities, and lack of signiﬁcant honeycombing. The ab-
normalities were stated to have signiﬁcantly progressed since
September 2011.td. This is an open access article uThe patient was thought to have community acquired pneu-
monia on top of pre-existing asbestosis and interstitial lung disease.
Video-assisted thoracoscopic lung biopsy was performed on
January 21, 2014. Preoperative and post-operative diagnoses were:
1) probable interstitial lung disease; 2) asbestosis; and 3) atrial
arrhythmia. Operative ﬁndings stated the surface of the right lung
was abnormal. Wedge biopsies of the right middle and lower lobes
were obtained and pathologic evaluation revealed patchy intersti-
tial ﬁbrosis with chronic inﬂammation consistent with usual
interstitial pneumonia (UIP), with focal organizing pneumonia and
progression toward end-stage lung.
A progress note dated January 23, 2014 stated the patient was to
remain on ceftriaxone for 14 days; IV steroids for interstitial lung
disease; metoprolol for atrial ﬁbrillation; Prevacid for gastrointes-
tinal (GI) prophylaxis; Dilaudid for pain control; enoxaparin (hep-
arin) for DVT prophylaxis; and N-acetyl cysteine (NAC) 600 mg BID.
The patient started coughing up bloody mucus on 1/23/14. His
chest tube was removed on post-op day #4 and hewas restarted on
20 mg of Xarelto every evening between 1/26/14 and time of
discharge on 2/7/14. He was also started on IV Lasix without
improvement so his Lasix was increased to 40 mg BID IV. Upon
discharge from the hospital, he was switched to oral furosemide
(Lasix) 40 mg daily for 30 days.
The patient had a prolonged hospital stay (26 days) and was
discharged home to hospice care with a prognosis of two weeks to
one year. He had severe dyspnea onminimal exertion. In fact, in the
course of one month, he progressed from being ambulatory and
independent to being oxygen-dependent and requiring complete
care. He continued his prescription of 20 mg of Xarelto at home.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Macroscopic appearance of lung.
Fig. 2. Macroscopic appearance of lung.
Fig. 3. Extensive intrapulmonary hemorrhage.
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1. Prednisone 30 mg b.i.d.
2. Benzonatate 200 mg every 8 h PRN.
3. Diltiazem 240 mg every day.
4. Furosemide (Lasix) 40 mg daily.
5. Prevacid 30 mg every day.
6. Toprol-XL 25 mg every day.
7. Morphine sublingual 5e10 mg every 2 h PRN with 30 mL
dispensed.
8. Ativan 0.5e1 mg every 8 h PRN with #30 dispensed.
9. Rivaroxaban (Xarelto®) 20 mg daily [at home].
10. Metformin, 500 mg twice daily.
Discharge diagnoses were:
1. Idiopathic pulmonary ﬁbrosis, status-post open lung biopsy.
2. Asbestosis [note: this as a clinical diagnosis. While he had a
history of asbestos exposure, he did not have radiographic or
pathologic asbestosis].
3. Acute-on-chronic hypoxemic respiratory failure.
4. Atrial ﬁbrillation with rapid ventricular response.
5. Steroid-induced hyperglycemia treated with metformin.
6. Lower extremity edema from cor pulmonale and steroids,
treated with Lasix.
The patient's condition continued to deteriorate and he expired
on February 15, 2014. An autopsy was performed on February 19,
2014.
1.1. Autopsy ﬁndings
The decedent measured approximately 7100 to 7200 tall and
weighed an estimated 250 pounds. There was mild rigor and livor
mortis. Examination of the thorax revealed a scar at approximately
the 10th or 11th rib on the right. Ribs and sternum were normal.
The mediastinal tissue was normal. No hyaline pleural plaques
were identiﬁed. The pleural cavities did not contain ﬂuid. The tra-
chea was normal.
The right lung, ﬁxed, weighed 1231.5 g and measured approxi-
mately 22  16  12 cm. The surface of the right lung was hem-
orrhagic with petechiae and was somewhat nodular. The visceral
pleural surface was ﬁnely nodular. Upon sectioning, the paren-
chyma was extremely hemorrhagic. There were a few nodules on
the pleural surface. No thrombi or thromboemboli were identiﬁed.
There were no hyaline pleural plaques on the visceral or parietal
pleura, including the surface of the lungs.
The superior vena cava was normal. The heart was in its usual
anatomic position and appeared normal. No tumor was identiﬁed
on the pericardium. Therewas blood on the parietal pleural surface.
There did not appear to be blood in the trachea or bronchi.
The left lung, ﬁxed, weighed 1038 g and measured approxi-
mately 22 15 8 cm. Therewas nodularity on the visceral pleural
surface. The surface of the left lung was hemorrhagic with pete-
chiae. Upon sectioning, the parenchyma was extensively
hemorrhagic.
The macroscopic appearance of the lungs is shown in Figs. 1 and
2.
Microscopically, the lungs showed extensive hemorrhage
(Fig. 3) with ﬁlling of alveolar spaces with fresh blood. There were
areas of hyaline membrane formation (Fig. 4) with bright red ma-
terial lining the alveolar spaces. There was subpleural interstitial
ﬁbrosis with some honeycombing, the ﬁndings being consistent
with usual interstitial pneumonia (Fig. 5). There was mild inter-
stitial ﬁbrosis. There were aggregates of macrophages in alveolarspaces. No neoplasm was identiﬁed. Trichrome stained sections
showed peripheral interstitial ﬁbrosis and blood (Fig. 6). Iron stains
showed hemosiderin (Figs. 7 and 8).
2. Acute lung injury of unknown cause
We evaluated reports in the literature concerning acute exac-
erbation (acute lung injury of unknown cause) in UIP and other
forms of ﬁbrotic interstitial pneumonias [1e4]. These reports of
acute lung injury did not provide any mechanism by which these
acute processes developed. In the report by Swigris et al. [2], the
Fig. 4. Hyaline membrane formation.
Fig. 5. Usual interstitial pneumonia (UIP).
Fig. 6. Peripheral interstitial ﬁbrosis and blood.
Fig. 7. Hemosiderin.
Fig. 8. Hemosiderin.
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stitial pneumonia (AIP), approximately two-thirds of patients had
symptoms for less than 1 week before diagnosis, while the
remaining one-third had symptoms up to 60 days prior topresentation. Differential diagnosis of AIP included essentially all
causes of acute lung injury (e.g., infection, acute inﬂammatory lung
diseases such as acute eosinophilic pneumonia or diffuse alveolar
hemorrhage, aspiration, drug-induced lung disease, nonpulmonary
disorders leading to a systemic inﬂammatory response such as
pancreatitis or underlying connective tissue disease, heart failure,
etc.). The authors stated that, generally, there were no speciﬁc
clinical clues that helped differentiate AIP from known causes of
acute respiratory distress syndrome (ARDS) and that most patients
(over 70%) succumbed to the disease within two weeks of
diagnosis.
Collard et al. [3] stated the natural history of idiopathic pul-
monary ﬁbrosis (IPF) had been characterized as a steady, predict-
able decline in lung function over time, but that more recent
studies suggested that some patients may develop acute deterio-
ration in respiratory status of unknown etiology (termed acute
exacerbations of IPF). The authors stated the etiology of acute
exacerbation of IPF was unknown, although they listed three
competing hypotheses for which no consensus could be reached.
Churg et al. [4] published an article in the American Journal of
Surgical Pathology in 2007 concerning acute exacerbation in usual
interstitial pneumonia (UIP) and other forms of ﬁbrotic interstitial
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lying UIP, 2 with underlying ﬁbrotic nonspeciﬁc interstitial pneu-
monia, and 1 with underlying chronic hypersensitivity
pneumonitis. Ten patients survived the acute episode, however, the
two patients who died had histologic diffuse alveolar damage. The
authors concluded that acute exacerbation of UIP and other ﬁbrotic
lung diseases produces a variety of pathologic patterns on biopsy
and patients with organizing pneumonia or extensive ﬁbroblastic
foci as the acute pattern seem to do better than those with diffuse
alveolar damage (DAD).
3. Hemorrhagic events during anticoagulation therapy
Anticoagulation therapy is frequently given as a prophylaxis for
deep venous thrombosis (blood clot) following total hip replace-
ment and total knee replacement, although the main complication
of anticoagulation therapy is risk of bleeding, even when thera-
peutic control is achieved. Low-molecular-weight heparin products
such as enoxaparin can be administered to reverse the effects of
acute bleeding in approximately 60% of cases and is associated with
a statistically reduced mortality risk compared with unfractionated
heparin [5].
According to a report by Smythe et al. [6] concerning rivarox-
aban (Xarelto®) and practical considerations for ensuring safety and
efﬁcacy, rivaroxaban is one of a new generation of anticoagulants
called direct factor Xa inhibitors used in the U.S. for the prevention
of stroke and systemic embolism in patients with non-valvular
atrial ﬁbrillation and which was also approved by the FDA for use
in people who have just undergone hip or knee replacement sur-
gery to reduce the risk of deep vein thrombosis (DVT) and pul-
monary embolism (PE). As a result of pharmacokinetics and
pharmacodynamics, a ﬁxed dose of rivaroxaban is administered
without routine coagulation testing. The authors stated rivarox-
aban has a short half-life, undergoes a dual mode of elimination
(hepatic and renal), and is a substrate of P-glycoprotein. It has a
lower potential for drug interactions compared with warfarin.
Injectable (intravenous) and oral anticoagulant agents are widely
used for the prevention and treatment of venous and arterial
thrombosis, which is associated with signiﬁcant morbidity and
mortality.
After a 5 mg dose of rivaroxaban, there is 22% maximum FXa
inhibition, which increases to 68% after a 30-mg dose. Maximum
inhibition occurs 1e4 h after dosing. There has been an increasing
desire to measure rivaroxaban's anticoagulant effect reliably,
however, current limitations include the lack of routinely available
standardized, validated assays with established target ranges as
well as the lack of an established relationship of laboratory pa-
rameters to clinically important outcomes. The authors [6] reported
the potential scenarios for measuring a prothrombin time (PT) in
rivaroxaban patients. For example, in cases of suspected over-
anticoagulation, a linear relationship exists between increasing
rivaroxaban concentration and increasing prothrombin time (PT).
Excessive prolongationmay signal over-anticoagulation. As a result,
one must combine interpretation of prothrombin time results with
clinical assessment. Also, after administration of blood products
and/or clotting factors in cases of over-anticoagulation, reversal of
PT may not correlate with cessation of bleeding. Therefore,
continued prolongation or rebound may require repeated admin-
istration of blood products and/or concentrated clotting factor. The
authors noted that it is unclear if the normalization of the PT in-
dicates reversal of drug effect when using a concentrated clotting
factor product.
Rivaroxaban and other anticoagulants require special care when
managing use around invasive procedures. Recommendations for
the time period towithhold the drug prior to an invasive procedurevaried from 2 to 6 days. Because of this, individualized assessment
of the thrombosis versus bleeding risk is necessary. The combina-
tion of rivaroxaban and other anticoagulants, antiplatelet drugs, or
ﬁbrinolytics increase the risk of hemorrhage. Because many hos-
pitals and health systems are unfamiliar with rivaroxaban and its
pharmacologic proﬁle, unintentional combination therapy can
occur. Concurrent use of rivaroxaban with warfarin, dabigatran,
apixaban, heparin, low-molecular weight heparin (enoxaparin,
dalteparin, tinzaparin), fondaparinux, and intravenous direct
thrombin inhibitors (DTIs) such as argatroban, bivalirudin, lepir-
udin, and desirudin should be avoided with the exception of short-
term overlap during transition from one anticoagulant to another. It
was noted that healthcare providers should avoid concurrent an-
tiplatelet therapy when there is no compelling indication, keeping
the current aspirin dose under 100 mg/day when needed and using
warfarin instead of rivaroxabanwhen triple antithrombotic therapy
is needed.
The authors [6] listed potential drug interactions with rivarox-
aban in Table 7 on page 1235 of their report. The authors stated that
because of rivaroxaban's balanced renal and hepatic elimination,
current U.S. rivaroxaban labeling indicates that the only clinically
signiﬁcant drug interactions identiﬁed to date are those involving
combined use of a strong CYP3A4 inhibitor with a P-glycoprotein
inhibitor or combined use of a strong CYP3A inducer with a P-
glycoprotein inducer.
Another important and challenging factor in managing rivar-
oxaban is to ensure that the dose is correct for the patient's indi-
cation and comorbidities. There are two different doses approved
for non-valvular atrial ﬁbrillation (NVAF) based on the patient's
renal function; two different doses approved for venous throm-
boembolism (VTE) based on timing from the event; and a much
lower dose studied for acute coronary syndrome (ACS). Each of
these doses is different from orthopedic VTE prophylaxis dose. In
addition, the creatinine clearance at which dose reduction is
required varies by indication. The authors [6] stated certain chal-
lenges will arise when a patient on rivaroxaban for one indication
develops another condition for which rivaroxaban is indicated but
at a different dose regimen. Clinicians are cautioned against using
15 or 20-mg/day dose for NVAF or VTE treatment, or as a secondary
prophylaxis immediately following elective orthopedic or other
procedures with a high bleeding risk. The authors [6] urge health
systems to develop a system that identiﬁes who prescribes the
initial 15-mg twice/day dose for 21 days versus who prescribes the
20 mg/day long-term dose and how this transition in care happens
safely and effectively. A person's body weight and dosage is also a
factor as shown in Table 8 on page 1238 of the article.
While evaluating our case, we did an extensive MedLine search
to see if there might be any other conditions that would account for
this patient's pulmonary hemorrhage. Death as a result of Xarelto®
as well as related generic and/or brand-name drugs containing the
same primary active ingredients reported to the FDA between the
1st quarter of 2004 and the 3rd quarter of 2012 was 101 (1.03%);
note: this percentage was stated to represent the percentage of
deaths to all adverse events reported and not to drug utilization.
According to the website Institute for Safe Medication Practices
[7], warfarin (Coumadin) and newcomers dabigatran (Pradaxa) and
rivaroxaban (Xarelto) counted for 1734 reports to the FDA in the
2nd quarter of 2012, including 233 patient deaths, reinforcing the
conclusion that anticoagulants rank among the highest risk of all
outpatient drug treatments. In fact, excessive bleeding as a result of
dabigatran (Pradaxa) was about 5x more likely than warfarin to
result in death (19% versus 4%, adjusted OR 5.2; 95% CI 3.4e8.0). As
for rivaroxaban, an additional quarter of data conﬁrmed an earlier
ﬁnding that blood clot-related events were reported more
frequently in patients receiving the 10 mg/daily dose after hip or
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patients with non-valvular atrial ﬁbrillation, which raised the
concern whether the 10 mg dose was suboptimal. Embolic-
thrombotic events such as pulmonary embolism (PE) and deep
vein thrombosis (DVT) were much more likely to be reported in
lower dose patients after surgery compared to atrial ﬁbrillation
patients with twice the recommended daily dose (56% vs. 17%,
adjusted OR 7.0; 95% CI 3.9e12.6). Of the three anticoagulants, only
rivaroxaban had a 50% lower recommended dose for hip/knee
surgery compared to its other indications.
The German newspaper Der Speigel stated that at least 968
adverse events involving Xarelto were reported to German health
ofﬁcials in the ﬁrst eight months of 2013, including 72 deaths. The
numbers compare to 750 adverse events and 58 deaths throughout
all of the previous year, indicating that the increase tracked with
the rise in use of Xarelto, which had reportedly increased 240% after
just 11/2 years on the market. There have also been concerns about
the use of Pradaxa, which began shortly after the medication was
introduced in October 2010. Pradaxa quickly became one of the
medications most commonly associated with adverse events re-
ported to the FDA. The FDA received at least 3781 reports involving
serious injuries associated with the use of Pradaxa during 2011,
including 2367 reports of hemorrhage and 542 deaths.
4. Conclusion
With respect to our case, there was no indication that our pa-
tient's condition and subsequent demise were related to acute
exacerbation of IPF. While the intent of the physician(s) in our case
was to prevent post-operative blood clots by giving anticoagulation
medication, the opposite occurred; the patient was actually hem-
orrhaging into his lungs as conﬁrmed by postmortem evaluation of
lung tissue, which showed extensive acute lung injury/hemorrhage
as a result of anticoagulation therapy.
While rivaroxaban (Xarelto®), which has been marketed as a
replacement for warfarin (Coumadin), like all blood thinners,
carries a risk of bleeding, direct thrombin inhibitors and factor Xa
inhibitors such as rivaroxaban currently lack an effective reversal
agent such as vitamin K and plasma to reverse bleeding problems,making it more difﬁcult to prevent serious injury or death in pa-
tients taking rivaroxaban (Xarelto®).
Because of the potential serious and sometimes fatal side-effects
associated with the use of rivaroxaban and other similar drugs,
patients, family members, caregivers, and physicians should be
educated so they recognize the signs of bleeding (e.g., frequent or
prolonged bleeding from minor wounds such as from cuts while
shaving; bleeding around the gums and mucous membranes such
as during tooth brushing and nose blowing; heavy menstrual
bleeding; urine or stool discoloration; and easy bruising or hema-
tomas from daily activities such as carrying grocery bags or laundry
baskets) and seek urgent medical attention should such bleeding
occur.Conﬂict of interest
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